SD Biosensor Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for SD Biosensor.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	33.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SD Biosensor has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSE:A137310 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	654,489	-192,401	-180,043	-71,204	N/A
3/31/2024	649,665	-256,179	-280,627	-158,288	N/A
12/31/2023	655,677	-467,712	-386,749	-242,319	N/A
9/30/2023	693,451	-693,729	-140,618	37,220	N/A
6/30/2023	1,093,588	-208,280	233,279	405,806	N/A
3/31/2023	1,725,958	214,230	464,242	707,763	N/A
12/31/2022	2,932,001	911,362	583,761	889,008	N/A
9/30/2022	3,178,373	1,344,936	488,037	773,051	N/A
6/30/2022	3,153,907	1,175,426	736,314	1,002,780	N/A
3/31/2022	3,139,288	1,122,436	821,695	1,101,176	N/A
12/31/2021	2,929,961	1,088,471	1,042,912	1,234,945	N/A
9/30/2021	3,417,145	1,294,930	1,299,939	1,478,430	N/A
6/30/2021	3,426,350	1,269,537	880,600	1,053,264	N/A
3/31/2021	2,755,620	1,019,313	658,018	725,248	N/A
12/31/2020	1,686,163	615,636	440,232	495,382	N/A
12/31/2019	72,962	3,153	-9,128	-1,625	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A137310's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if A137310's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A137310's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A137310's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A137310's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A137310's Return on Equity is forecast to be high in 3 years time

SD Biosensor Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to ₩56,500

Consensus revenue estimates increase by 17%

Recent updates

What SD Biosensor, Inc's (KRX:137310) 25% Share Price Gain Is Not Telling You

Second quarter 2024 earnings released: ₩153 loss per share (vs ₩806 loss in 2Q 2023)

Would SD Biosensor (KRX:137310) Be Better Off With Less Debt?

Insufficient Growth At SD Biosensor, Inc (KRX:137310) Hampers Share Price

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: ₩91.00 loss per share (vs ₩2,177 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient Growth At SD Biosensor, Inc (KRX:137310) Hampers Share Price

Upcoming dividend of ₩290 per share at 8.7% yield

Third quarter 2023 earnings released: ₩552 loss per share (vs ₩4,166 profit in 3Q 2022)

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 23%

New minor risk - Share price stability

SD Biosensor, Inc has completed a Follow-on Equity Offering in the amount of KRW 227.8 billion.

Upcoming dividend of ₩700 per share at 7.5% yield

Now 21% undervalued after recent price drop

SD Biosensor, Inc. Proposes Discontuation of Use and Disposal of Specific Pilot COVID-19 At-Home Tests in the United States Due to Microbial Contamination in the Liquid Disposal Solution

Full year 2022 earnings: EPS and revenues miss analyst expectations

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Price target decreased to ₩56,500

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 17%

SD BioSensor, Inc (KOSE:A137310) agreed to acquire Relab S.R.L. for KRW 61.9 billion.

SD BioSensor, Inc (KOSE:A137310) acquired bestbion dx - Diagnostische Produkte und Beratung GmbH for KRW 16 billion.

Investor sentiment deteriorated over the past week

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies